CD70 and lung carcinoma: In conclusion, we are the first to demonstrate the immunotherapeutic potential of targeting CD70 in NSCLC with a maximum NK-cell mediated cytotoxicity of ARGX-110 in CD70 expressing lung cancer cell lines.